Zentalis Pharmaceuticals, Inc.
The company is dedicated to discovering and developing small molecule targeted therapeutics against fundamental biological pathways in cancer. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) in clinical trials for the treatment of advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative, and advanced or metastatic breast cancer.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 124 |
Founded | 2014 |
Financials | |
|---|---|
Market Capitalization | 281.92M |
Revenue | 40.56M |
Operating Income | -259.32M |
Operating Margin | -639.35% |
Net Income | -218.96M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5155 / 5373 |
Sector : Healthcare | 1065 / 1144 |
Industry : Biotechnology | 590 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3400 / 5565 |
Sector : Healthcare | 532 / 1182 |
Industry : Biotechnology | 262 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 5118 / 5436 |
Sector : Healthcare | 1061 / 1164 |
Industry : Biotechnology | 593 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3870 / 5330 |
Sector : Healthcare | 577 / 1174 |
Industry : Biotechnology | 214 / 667 |